Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Применение технологий редактирования генома в таргетной терапии человеческих заболеваний: механизмы, достижения и перспективы
2020-01-03
SCID: 54.1/sred78f4
Discuss with AI
CRISPR-Cas-associated nucleases (CRISPR/Cas9)clinical trials of genome editinggenome editingtranscription activator-like effector nucleases (TALENs)zinc-finger nucleases (ZFNs)
Figures from the paper
Abstract (AI)
Based on engineered or bacterial nucleases, the development of genome editing technologies has opened up the possibility of directly targeting and modifying genomic sequences in almost all eukaryotic cells. Genome editing has extended our ability to elucidate the contribution of genetics to disease by promoting the creation of more accurate cellular and animal models of pathological processes and has begun to show extraordinary potential in a variety of fields, ranging from basic research to applied biotechnology and biomedical research. Recent progress in developing programmable nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeat (CRISPR)-Cas-associated nucleases, has greatly expedited the progress of gene editing from concept to clinical practice. Here, we review recent advances of the three major genome editing technologies (ZFNs, TALENs, and CRISPR/Cas9) and discuss the applications of their derivative reagents as gene editing tools in various human diseases and potential future therapies, focusing on eukaryotic cells and animal models. Finally, we provide an overview of the clinical trials applying genome editing platforms for disease treatment and some of the challenges in the implementation of this technology.
Key Findings
1
Clinical trials are underway applying genome editing platforms for disease treatment, but challenges remain for implementation of the technology.
2
Derivative reagents from ZFNs, TALENs, and CRISPR/Cas9 are being applied as gene editing tools across various human diseases and potential therapies.
3
Engineered and bacterial nucleases enable direct targeting and modification of genomic sequences in almost all eukaryotic cells.
4
Genome editing facilitates creation of more accurate cellular and animal models, improving study of genetics' contribution to disease.
5
Programmable nucleases—ZFNs, TALENs, and CRISPR/Cas-associated nucleases—have accelerated gene editing from concept toward clinical practice.
Research Object
Genome editing technologies (ZFNs, TALENs, CRISPR/Cas9) and their derivative reagents applied to eukaryotic cells and animal models for targeted therapy of human diseases
Research Subject
Mechanisms, advances, applications and clinical prospects of these genome editing platforms for targeted therapy of human diseases, including development of cellular/animal disease models and clinical trial implementation challenges
Publication Details
Publication Date
2020-01-03
Journal
Publisher
ISSN
Cited by
1719
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
The new frontier of genome engineering with CRISPR-Cas92014
Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins2014
Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin2005
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases2013
Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies2015
Cited by4
p53 signaling in cancer progression and therapy2021
Multifunctional nanoparticle-mediated combining therapy for human diseases2023
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal2022
Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells2021